Lifeboat Foundation

Circa 2017

This review aims to highlight the key areas in which changes to the epigenome have played an important role in the evolution and development of our species. Firstly, there will be a brief introduction into the topic of epigenetics to outline the current understanding of the subject and inform the reader of the basic mechanisms and functions of the epigenome. This will lead on to more focussed detail on the role played by epigenetic changes in the rapid evolution of our species and emergence from our ancestor species, as well as the Human Accelerated Regions that played a role in this. The discussion highlights how epigenetics has helped and hindered our species’ development via changes to the epigenome in more modern times, discussing case examples of documented instances where it is shown that epigenetics has played a role in the evolution of humanity.

Harry Potter’s ‘invisibility cloak’ appears closer to reality as Canadian camouflage manufacturer Hyperstealth Biotechnology has applied for patents on its ‘Quantum Stealth’ material.

The ‘inexpensive and paper-thin’ technology works by bending light around a target to either alter its position or make it vanish altogether, leaving only the background visible. It is touted to be able to obscure the positions of heavy artillery, ground troops or even entire buildings from certain viewpoints.

Continue reading “‘Invisibility cloak’ that could hide tanks and troops looks closer to reality” »

Integrated Health Systems, in partnership with Maximum Life Foundation, is funding a trial to rejuvenate microglial cells using telomerase gene therapy. This trial is currently looking for ten patients with mild to moderate Alzheimer’s Disease. At this time five of the positions have been filled. The trial will be conducted in MONTEREY, Mexico. Treatment is …“Alzheimer’s Gene Therapy Human Study Seeks Volunteers”

Doctors in the Netherlands say they are within 10 years of creating a ‘second’ womb for premature babies.

Topological insulators are innovative materials that conduct electricity on the surface, but act as insulators on the inside. Physicists at the University of Basel and the Istanbul Technical University have begun investigating how they react to friction. Their experiment shows that the heat generated through friction is significantly lower than in conventional materials. This is due to a new quantum mechanism, the researchers report in the scientific journal Nature Materials.

Thanks to their unique electrical properties, topological insulators promise many innovations in the electronics and computer industries, as well as in the development of quantum computers. The thin surface layer can conduct electricity almost without resistance, resulting in less heat than traditional materials. This makes them of particular interest for electronic components.

“Our measurements clearly show that at certain voltages there is virtually no heat generation caused by electronic friction.” — Dr. Dilek Yildiz

The material has two major benefits for the climate.

Technology can change cultural norms. The way we think about the aging process is no exception. BioViva’s CEO Liz Parrish takes us on a quick tour through human history to show what used to be considered “normal” and what will be considered “normal” in the world of tomorrow.

The patent application for a “Plasma Compression Fusion Device” was applied for in March last year. It read, “Application filed by US Secretary of Navy.” The patent application was published in September this year. Under discussion is a compact fusion reactor.

The focus is on a compact nuclear fusion reactor that measures between 0.3 to 2 meters in diameter. As of October 15, the application status was listed as pending. The inventor named in the patent application was Salvatore Pais.

As described in The War Zone, the reactor could “pump out absolutely incredible amounts of power in a small space.”

Potential breakthrough technology for stem-cell based bone replacement

NEW YORK, May 22, 2019 /PRNewswire/ — EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1/2 clinical trial of its lead bone product EpiBone-Craniomaxillofacial (EB-CMF), as a potential treatment for ramus continuity defects in the mandible. The ramus is a key component of the jaw bone which attaches to the muscles associated with chewing.

EB-CMF is a living anatomically correct bone graft manufactured from a patient’s own adipose derived stem cells. This eliminates the need to harvest bone from a patient’s body, potentially reducing pain, surgical and hospitalization time while creating a precision fit with the defect.